Market Research Logo

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 analyzes the leading concerns in the pharmaceutical industry, including the late-term pipeline of major competitors. This report provides long-term company sales forecasts based recent market conditions. For each company covered, the report includes late stage product pipeline; late stage product pipeline by therapeutic area, comparing 2009, 2011, 2013 and 2015; total company revenue and total R&D spending, 2011-2015; leading pharmaceutical products, 2015 sales; break-up of sales by region, 2015; pharmaceutical segment sales, 2011 through 2015 and forecasted 2025; and pharmaceutical business performance, 2011-2015 and forecasted 2025. Merck, Novartis, Pfizer, Roche, and Sanofi are among the top manufacturers examined.


  • Executive Summary
    • INTRODUCTION
    • SCOPE AND METHODOLOGY
      • Table Global Pharmaceutical Projects in Development by Therapeutic Segment
    • FUTURE MARKET OPPORTUNITY
      • Table Figure 1 1 Global Pharmaceutical Market, 2011 2015 and Forecasted 2025
    • LEADING COMPANIES
      • Table Leading Pharmaceutical Companies
    • CONCLUSIONS
  • Introduction
    • GLOBAL PHARMACEUTICAL MARKET
      • Table Figure 2 1 Global Pharmaceutical Market by Therapeutic Area, 2011 2015 and Forecasted 2025
    • TOP 25 PHARMACEUTICAL COMPANIES: AN OVERVIEW
      • Table Top Pharmaceutical Companies, 1 25 by 2015 Pharmaceutical Sales ($ millions)
      • Table Figure 2 2 Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales, 2015
    • GLOBAL HEALTHCARE SPENDING
      • Table Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2015 Estimates
    • AGING POPULATION AND IMPACT ON PHARMACEUTICAL MARKETS
      • Table Figure 2 3 International Population Trend Age 65+ (Thousands)
  • Trends in Pharmaceutical Research and Development
    • PHARMACEUTICAL RESEARCH & DEVELOPMENT CHALLENGE
    • THE DRUG APPROVAL PROCESS
      • Percent of Approvals
      • Selecting Better Targets
        • Table Phases of Clinical Drug Development
      • Top R&D Spenders
        • Table Top R&D Spenders in the Pharmaceutical Industry - 2013, 2014 and 2015 (in millions)
        • Table Figure 3 1 Top 10 R&D Spenders in the Pharmaceutical Industry, 2015 Comparison by Company
      • The Pipeline Snapshot
        • Table Figure 3 2 Company Pipelines by Total Late Stage Development Projects (Top 25 Companies by Revenues)
        • Table Figure 3 3 Cardiovascular/Blood Pipeline Leaders, 2015
        • Table Figure 3 4 Neurotherapeutics Pipeline Leaders, 2015
        • Table Figure 3 5 Infectious Disease Pipeline Leaders, 2015
        • Table Figure 3 6 Oncology Pipeline Leaders, 2015
        • Table Figure 3 7 Respiratory/Inflammation Pipeline Leaders, 2015
        • Table Figure 3 8 Other Therapy Pipeline Leaders, 2015
    • EXPANDED OPTIONS IN TREATING DISEASES
    • BIOTECHNOLOGY DRUG DEVELOPMENT
    • ORPHAN DRUGS
      • Table Orphan Drug Designations Granted and Approved by the FDA 1983 2016
    • FAST TRACK DRUG STATUS
      • Table Examples of Fast Track Drugs Withdrawn from Market
    • OTHER ACCELERATED METHODS FOR DRUG APPROVAL
      • Breakthrough Therapy
    • PHARMACEUTICAL REGULATORY EXCLUSIVITY
      • Pediatric Extensions
    • THE ROLE OF CONTRACT RESEARCH ORGANIZATIONS
  • Pfizer, Inc.
    • COMPANY OVERVIEW
      • Table Pfizer Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Pfizer: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
      • Geographic Market Participation
        • Table Figure 4 1 Pfizer: Break up of Total Revenues by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 4 2 Pfizer: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 4 3 Pfizer: Pharmaceutical Segment Sales, 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Pfizer: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Pfizer: Late Stage Product Pipeline
      • Table Figure 4 4 Pfizer: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Novartis International AG
    • COMPANY OVERVIEW
      • Table Novartis Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Novartis: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 5 1 Novartis: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 5 2 Novartis: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 5 3 Novartis: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Novartis: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Novartis: Late Stage Product Pipeline
      • Table Figure 5 4 Novartis: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Roche Ltd.
    • OVERVIEW
      • Table Roche Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Roche: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 6 1 Roche: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 6 2 Roche: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 6 3 Roche: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Roche: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Roche: Late Stage Product Pipeline
      • Table Figure 6 4 Roche: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Merck & Co., Inc.
    • COMPANY OVERVIEW
      • Table Merck Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Merck: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 7 1 Merck: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 7 2 Merck: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 7 3 Merck: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Merck: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Merck: Late Stage Product Pipeline
      • Table Figure 7 4 Merck: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Sanofi
    • COMPANY OVERVIEW
      • Table Sanofi Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Sanofi Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 8 1 Sanofi: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 8 2 Sanofi: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 8 3 Sanofi: Pharmaceutical Segment Sales, 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Sanofi: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Sanofi Late Stage Product Pipeline
      • Table Figure 8 4 Sanofi: Late Stage Product Pipeline by Therapeutic Area, Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Gilead Sciences
    • COMPANY OVERVIEW
      • Table Gilead Sciences Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Gilead Sciences: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 9 1 Gilead Sciences: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 9 2 Gilead Sciences: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 9 3 Gilead Sciences: Pharmaceutical Segment Sales, 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Gilead Sciences: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Gilead Sciences: Late Stage Product Pipeline
      • Table Figure 9 4 Gilead Sciences: Late Stage Product Pipeline by Therapeutic Area, Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Gilead Sciences: Highlighted Corporate Developments
  • Johnson & Johnson
    • COMPANY OVERVIEW
      • Table Johnson & Johnson Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Johnson & Johnson: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 10 1 Johnson & Johnson: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 10 2 Johnson & Johnson: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 10 3 Johnson & Johnson: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Johnson & Johnson: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Johnson & Johnson: Late Stage Product Pipeline
      • Table Figure 10 4 Johnson & Johnson: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • GlaxoSmithKline plc
    • COMPANY OVERVIEW
      • Table GlaxoSmithKline Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table GlaxoSmithKline: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 11 1 GlaxoSmithKline: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 11 2 GlaxoSmithKline: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 11 3 GlaxoSmithKline: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table GlaxoSmithKline: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table GlaxoSmithKline: Late Stage Product Pipeline
      • Table Figure 11 4 GlaxoSmithKline: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • AstraZeneca plc
    • COMPANY OVERVIEW
      • Table AstraZeneca Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table AstraZeneca: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 12 1 AstraZeneca: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 12 2 AstraZeneca: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 12 3 AstraZeneca: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table AstraZeneca: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table AstraZeneca: Late Stage Product Pipeline
      • Table Figure 12 4 AstraZeneca: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • AbbVie, Inc.
    • COMPANY OVERVIEW
      • Table AbbVie Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table AbbVie: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 13 1 AbbVie: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 13 2 AbbVie: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table AbbVie: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table AbbVie: Late Stage Product Pipeline
      • Table Figure 13 3 AbbVie: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Amgen, Inc.
    • COMPANY OVERVIEW
      • Table Amgen Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Amgen: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 14 1 Amgen: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 14 2 Amgen: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 14 3 Amgen: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Amgen: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Amgen: Late Stage Product Pipeline
      • Table Figure 14 4 Amgen: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • TEVA Pharmaceutical Industries, Ltd.
    • COMPANY OVERVIEW
      • Table Teva Pharmaceutical Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Teva Pharmaceutical: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 15 1 Teva Pharmaceutical: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 15 2 Teva Pharmaceutical: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 15 3 Teva Pharmaceutical: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Teva Pharmaceutical: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Teva Pharmaceutical: Late Stage Product Pipeline Brand Development
      • Table Figure 15 4 Teva Pharmaceutical: Late Stage Product Pipeline by Therapeutic Area (Brand Therapeutics) Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Eli Lilly and Company
    • COMPANY OVERVIEW
      • Table Eli Lilly Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Eli Lilly's Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 16 1 Eli Lilly & Co.: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 16 2 Eli Lilly & Co.: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 16 3 Eli Lilly & Co.: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Eli Lilly & Co.: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Eli Lilly: Late Stage Product Pipeline
      • Table Figure 16 4 Eli Lilly & Co.: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Bristol-Myers Squibb Company
    • COMPANY OVERVIEW
      • Table Bristol Myers Squibb Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Bristol Myers Squibb's Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 17 1 Bristol Myers Squibb: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 17 2 Bristol Myers Squibb: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025,($millions)
      • Table Figure 17 3 Bristol Myers Squibb: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Bristol Myers Squibb: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Bristol Myers Squibb: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Bristol Myers Squibb Highlighted Corporate Developments
  • Novo Nordisk
    • COMPANY OVERVIEW
      • Table Novo Nordisk Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Novo Nordisk: Total Company Revenue and Total R&D Spending 2011 2015 (millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 18 1 Novo Nordisk: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 18 2 Novo Nordisk: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 18 3 Novo Nordisk: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Novo Nordisk: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Novo Nordisk: Late Stage Product Pipeline
      • Table Figure 18 4 Novo Nordisk: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Bayer AG
    • COMPANY OVERVIEW
      • Table Bayer Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Bayer's Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 19 1 Bayer: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 19 2 Bayer: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 19 3 Bayer: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Bayer: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Bayer: Late Stage Product Pipeline
      • Table Figure 19 4 Bayer: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Takeda Pharmaceutical Co., Ltd.
    • COMPANY OVERVIEW
      • Table Takeda Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Takeda's Total Company Revenue* and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 20 1 Takeda: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 20 2 Takeda: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 20 3 Takeda: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Takeda: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Takeda Pharmaceutical: Late Stage Product Pipeline
      • Table Figure 20 4 Takeda: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Boehringer Ingelheim GmbH
    • COMPANY OVERVIEW
      • Table Boehringer Ingelheim Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Boehringer Ingelheim: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 21 1 Boehringer Ingelheim: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 21 2 Boehringer Ingelheim: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 21 3 Boehringer Ingelheim: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Boehringer Ingelheim: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Boehringer Ingelheim: Late Stage Product Pipeline
      • Table Figure 21 4 Boehringer Ingelheim: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Allergan PLC
    • COMPANY OVERVIEW
      • Table Allergan plc Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Allergan: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 22 1 Allergan: Pharmaceutical Business Performance, 2014 2015 and Forecasted 2025 ($millions)
      • Table Figure 22 2 Allergan: Pharmaceutical Segment Sales 2014 2015 and Forecasted 2025
    • LATE STAGE PIPELINE
      • Table Allergan: Late Stage Product Pipeline Brand Development
    • GROWTH STRATEGY
      • Table Allergan: Highlighted Corporate Developments
  • Astellas Pharma, Inc.
    • COMPANY OVERVIEW
      • Table Astellas Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Astellas: Total Company Revenue and Total R&D Spending 2011 2015 (millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 23 1 Astellas: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 23 2 Astellas: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 23 3 Astellas: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Astellas: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Astellas: Late Stage Product Pipeline
      • Table Figure 23 4 Astellas: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Mylan, Inc.
    • COMPANY OVERVIEW
      • Table Mylan Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Mylan: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 24 1 Mylan: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 24 2 Mylan: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 24 3 Mylan: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
    • PIPELINE
    • GROWTH STRATEGY
      • Table Corporate Development Details
  • Biogen, Inc.
    • COMPANY OVERVIEW
      • Table Biogen Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Biogen: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 25 1 Biogen: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 25 2 Biogen: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 25 3 Biogen: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Biogen: Leading Pharmaceutical Products, 2015 Sales (millions)
    • PIPELINE
      • Table Biogen: Late Stage Product Pipeline
      • Table Figure 25 4 Biogen: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011 and 2013
    • GROWTH STRATEGY
      • Table Biogen: Highlighted Corporate Developments
  • Celgene Corporation
    • COMPANY OVERVIEW
      • Table Celgene Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Celgene: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 26 1 Celgene: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 26 2 Celgene: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 26 3 Celgene: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Celgene: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Celgene: Late Stage Product Pipeline
      • Table Figure 26 4 Celgene: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Celgene: Corporate Development Details
  • Otsuka Pharmaceutical
    • COMPANY OVERVIEW
      • Table Otsuka Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Otsuka Holdings: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 27 1 Otsuka Holdings: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 27 2 Otsuka Holdings: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2023 ($millions)
      • Table Figure 27 3 Otsuka Holdings: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Otsuka Holdings: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Otsuka Holdings: Late Stage Product Pipeline
      • Table Figure 27 4 Otsuka Holdings: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Daiichi Sankyo
    • COMPANY OVERVIEW
      • Table Daiichi Sankyo Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Daiichi Sankyo: Total Company Revenue and Total R&D Spending 2011 2015 (millions)
    • GEOGRAPHIC MARKET PARTICIPATION
      • Table Figure 28 1 Daiichi Sankyo: Break up of Sales by Region, 2015 (in percent)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Table Figure 28 2 Daiichi Sankyo: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      • Table Figure 28 3 Daiichi Sankyo: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
      • Leading Products
        • Table Daiichi Sankyo: Leading Pharmaceutical Products, 2015 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Daiichi Sankyo: Late Stage Product Pipeline
      • Table Figure 28 4 Daiichi Sankyo: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Market Summary and Forecast Analysis
    • COMPANY OVERVIEW
      • Table Global Pharmaceutical Market, 2011 2015 and Forecasted 2025($ in billions)
      • Table Figure 29 1 Global Pharmaceutical Market, 2011 2015 and Forecasted 2025
    • MARKET TRENDS AND VALUES BY THERAPEUTIC AREA
      • Table Figure 29 2 Global Pharmaceutical Market by Therapeutic Area, 2011 2015 and Forecasted 2025
      • Cardiovascular/Blood Market Analysis
        • Table Figure 29 3 Top 5 Cardiovascular/Blood Therapeutic Companies, 2015 Sales
      • Neurotherapeutics Market Analysis
        • Table Figure 29 4 Top 5 Neurotherapeutic Companies, 2015 Sales
      • Infection Treatments Market Analysis
        • Table Figure 29 5 Top 5 Infection Treatment Companies, 2015 Sales
      • Oncology Market Analysis
        • Table Figure 29 6 Top 5 Oncology Companies, 2015 Sales
      • Respiratory and Inflammation Market Analysis
        • Table Figure 29 6 Top 5 Respiratory and Inflammation Product Companies, 2015 Sales
      • Other Drug Market Analysis
        • Table Figure 29 7 Top 5 Other Drug Companies, 2015 Sales
    • EVALUATING CHANGES IN 2015 MARKET VALUE
      • Table Figure 29 8 Global Pharmaceutical Market % Change by Therapeutic Segment, 2014 2015
      • Year-over-Year Growth Analysis
        • Table Top Companies by 2015 Pharmaceutical Sales Growth ($ millions)
        • Table Figure 29 9 Global Pharmaceutical Market, Sales Growth by Company, 2014 2015
    • COMPANY ANALYSIS
      • Table Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales 2015 Compared to 2011 and 2013 (millions)
      • Table Top 50 Pharmaceutical Products, by 2013 and 2015 Revenues (billions)
    • MARKET FORECAST
      • Table Global Pharmaceutical Market Forecast by Therapeutic Segment, 2025-based on late stage development projects evaluated ($ in billions)
      • Table Figure 29 11 Global Pharmaceutical Market Forecast by Therapeutic Segment, 2025-based on late stage development projects evaluated
    • FUTURE COMPANY OUTLOOK
      • Table Evaluating Pharmaceutical Company Growth, 2015 2025 ($ millions)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report